The Nanotechnology Characterization Laboratory (NCL) is collaborating with the Army to develop a candidate vaccine against botulism.

Under a collaboration agreement between the National Cancer Institute and the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), NCL scientists will produce nanoparticle formulations for four compounds that block the activity of botulism-causing nerve toxins, which are among the most lethal of all poisons.

Pages